Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase 1 Study of AK006 in Healthy Participants and Chronic Spontaneous Urticaria
NCT06072157Phase 1Completed
- Sponsor
- Allakos Inc.
- Start
- Aug 2023
- Primary completion
- May 2025
- Modality
- Monoclonal Antibodies
- Countries
- 2
01
Overview
Phase 1, randomised, double-blind trial of AK006 in chronic spontaneous urticaria (CSU) (4 arms), sponsored by Allakos Inc. Primary endpoints: Incidence and severity of adverse events and Incidence of clinically significant abnormal laboratory values, ECGs, and vital signs. Started Aug 2023; status: completed.
02
Drugs
AK006
03
Conditions
chronic spontaneous urticaria (CSU)
Beyond the preview
Go deeper on NCT06072157.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT06072157.